Atria Investments LLC Has $1.85 Million Stock Position in Sanofi (NASDAQ:SNY)

Atria Investments LLC raised its holdings in Sanofi (NASDAQ:SNY) by 23.5% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 35,161 shares of the company’s stock after buying an additional 6,701 shares during the quarter. Atria Investments LLC’s holdings in Sanofi were worth $1,852,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Knowledge Leaders Capital LLC lifted its stake in Sanofi by 1.2% in the second quarter. Knowledge Leaders Capital LLC now owns 16,434 shares of the company’s stock valued at $865,000 after buying an additional 198 shares during the period. Ingalls & Snyder LLC lifted its stake in Sanofi by 2.2% in the second quarter. Ingalls & Snyder LLC now owns 9,345 shares of the company’s stock valued at $492,000 after buying an additional 200 shares during the period. Raymond James Trust N.A. lifted its stake in Sanofi by 1.1% in the second quarter. Raymond James Trust N.A. now owns 18,691 shares of the company’s stock valued at $984,000 after buying an additional 203 shares during the period. Clarius Group LLC lifted its stake in Sanofi by 3.7% in the second quarter. Clarius Group LLC now owns 5,948 shares of the company’s stock valued at $313,000 after buying an additional 211 shares during the period. Finally, Meridian Wealth Partners LLC raised its position in shares of Sanofi by 46.6% during the first quarter. Meridian Wealth Partners LLC now owns 777 shares of the company’s stock worth $39,000 after purchasing an additional 247 shares during the period. 8.02% of the stock is currently owned by hedge funds and other institutional investors.

In related news, major shareholder Sanofi acquired 66,667 shares of the company’s stock in a transaction on Monday, August 2nd. The shares were acquired at an average cost of $15.00 per share, for a total transaction of $1,000,005.00. The acquisition was disclosed in a document filed with the SEC, which is available at this link. 1.00% of the stock is currently owned by company insiders.

A number of equities analysts recently issued reports on the company. UBS Group reiterated a “buy” rating on shares of Sanofi in a report on Thursday, August 12th. JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Sanofi in a report on Friday, July 30th. Finally, Morgan Stanley reiterated an “overweight” rating on shares of Sanofi in a report on Friday, August 6th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $53.00.

Shares of NASDAQ:SNY opened at $48.38 on Friday. The company has a current ratio of 1.54, a quick ratio of 1.06 and a debt-to-equity ratio of 0.28. The stock’s fifty day simple moving average is $51.24 and its two-hundred day simple moving average is $51.23. Sanofi has a 1-year low of $44.76 and a 1-year high of $54.26. The stock has a market cap of $121.99 billion, a PE ratio of 17.59, a price-to-earnings-growth ratio of 1.38 and a beta of 0.56.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings data on Thursday, July 29th. The company reported $0.83 earnings per share for the quarter, beating the consensus estimate of $0.79 by $0.04. Sanofi had a return on equity of 24.31% and a net margin of 16.02%. The business had revenue of $10.53 billion for the quarter, compared to analysts’ expectations of $10.29 billion. On average, sell-side analysts forecast that Sanofi will post 3.85 earnings per share for the current fiscal year.

Sanofi Profile

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities.

Further Reading: Stocks Increasing Dividends

Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNY).

Institutional Ownership by Quarter for Sanofi (NASDAQ:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.